Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 0429ac)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of the antineoplastic agents cytarabine and daunorubicin in a fixed 5:1 molar ratio. This formulation is designed to deliver a synergistic ratio of the two drugs directly to the bone marrow, enhancing efficacy while potentially reducing systemic toxicity compared to conventional chemotherapy. Cytarabine is a pyrimidine analog that inhibits DNA polymerase, while daunorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. CPX-351 is FDA-approved for the treatment of adults and pediatric patients (1 year and older) with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It was originally developed by Celator Pharmaceuticals and is currently marketed by Jazz Pharmaceuticals.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposomedaunorubicin + cytarabine liposome
02
Targets
Nuclear DNA polymeraseDNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 0429ac).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 0429ac).